HKEX Review of the Stability of an Applicant's Core Technology R&D Team

The Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of the stability of an applicant’s core technology and R&D team, a shift that has direct implications for the viability of listing applications under Chapter 18C of the Main Board Listing Rules. This development, observed across a series of listing decisions and return comments in 2025, reflects a regulatory tightening aimed at ensuring that the “core technology” designation is not merely a marketing label but a verifiable, durable asset. For applicants, particularly those in the specialty technology and life sciences sectors, the stability of the R&D team is now a threshold question, not a disclosure detail. Without demonstrable evidence that the key technical personnel are contractually bound and operationally indispensable, a sponsor’s viability assessment under Listing Decision HKEX-LD133-2024 will face heightened challenge. This article examines the specific regulatory requirements, the evidentiary burden on sponsors, and the practical steps applicants must take to satisfy HKEX’s evolving standards.

The Regulatory Framework: From Guidance to Enforcement

HKEX Listing Decision HKEX-LD133-2024 and Its Implications

The HKEX’s Listing Decision HKEX-LD133-2024, published in December 2024, explicitly defines the criteria for assessing the stability of an applicant’s core technology R&D team. The decision requires that at least two of the applicant’s core technology personnel must have been with the company for a continuous period of at least three years prior to the listing application. This is not a soft guideline; it is a mandatory condition for applicants seeking to rely on the “core technology” exemption from the minimum market capitalisation requirement under Chapter 18C. The decision further mandates that the sponsor must confirm, through documented due diligence, that these individuals are bound by employment contracts with non-compete clauses and intellectual property assignment provisions that survive termination. As of Q1 2025, data from the HKEX’s pre-IPO enquiry statistics indicates that 14 of 22 applicant responses to first-round comments involved requests for further evidence on R&D team stability, with 8 of those resulting in a material delay to the listing timetable.

The Link to Chapter 18C and the “Specialist Technology Company” Regime

Chapter 18C, effective from 31 March 2023, introduced a streamlined pathway for specialist technology companies with a market capitalisation of at least HKD 10 billion (for commercialised companies) or HKD 20 billion (for pre-commercialised companies). The regime reduces the reliance on historical financial track records in favour of a qualitative assessment of the company’s core technology and its commercial viability. However, the HKEX has made clear that the stability of the R&D team is a proxy for the sustainability of that technology. In its 2025 thematic review of Chapter 18C applications, the HKEX noted that 17 of 34 applicants had to amend their prospectus disclosures to specifically address team stability after initial submissions. The regulator’s position is that a company’s “core technology” is only as stable as the team that developed and maintains it.

The Evidentiary Burden on Sponsors and Applicants

Documented Contractual Arrangements and Non-Compete Clauses

The sponsor’s due diligence must now include a forensic review of employment contracts, share option plans, and intellectual property assignment agreements for each key R&D personnel. The HKEX expects that these contracts contain specific non-compete clauses that are enforceable under the applicable law, typically the PRC, Hong Kong, or the jurisdiction of incorporation (e.g., Cayman Islands or BVI). In Listing Decision HKEX-LD133-2024, the exchange rejected an applicant’s reliance on a general non-disclosure agreement, requiring instead a dedicated non-compete provision that explicitly restricts the employee from engaging in any business that is “directly competitive” with the applicant’s core technology for a period of at least 12 months post-termination. Data from the Hong Kong Institute of Certified Public Accountants (HKICPA) shows that in 2024, 23% of Chapter 18C applicants had to renegotiate employment terms with at least one key R&D personnel to meet this standard.

The Role of the Sponsor in Verifying Team Stability

The sponsor must conduct independent verification of the R&D team’s stability, which includes reviewing the employment history of each core technology personnel for the preceding five years. This verification must address any gaps in employment, changes in job function, or periods of external consulting that could indicate a lack of commitment to the applicant. The HKEX’s return comments in 2025 have specifically targeted instances where a core technology personnel had a secondary role at a university or a research institute, requiring the sponsor to confirm that such external engagements do not conflict with the applicant’s intellectual property ownership. In one case, the HKEX required the sponsor to obtain a written waiver from the university confirming that no claim would be made on the applicant’s patents developed by the individual while employed.

Practical Challenges for Applicants in 2025-2026

The Problem of “Key Person” Dependency

A significant challenge arises when the R&D team’s stability is heavily reliant on a single individual, such as the founder or chief scientist. The HKEX’s 2025 guidance indicates that a team with only two core technology personnel, where one is the founder, will face additional scrutiny. The exchange requires evidence that the company’s R&D operations can continue in the event of that individual’s departure. This may involve demonstrating that a third or fourth key personnel is being groomed, or that the company’s patents and know-how are sufficiently documented to be transferable. Data from the HKEX’s pre-IPO review statistics shows that 9 of 12 applicants with a “key person” dependency had to provide a detailed succession plan and a key man insurance policy naming the company as beneficiary before their listing was approved.

The Impact of PRC Regulatory Changes on Cross-Border Teams

For applicants with R&D teams based in the PRC, the regulatory environment has become more complex following the PRC’s 2024 amendments to the Patent Law and the Technology Security Management Regulations. These changes require that any assignment of PRC-originated patents to an offshore parent company (e.g., Cayman or BVI) must be registered with the China National Intellectual Property Administration (CNIPA) and may be subject to a national security review if the technology is deemed “sensitive.” The HKEX has acknowledged this in its 2025 listing decisions, requiring sponsors to confirm that all patent assignments have been properly registered and that no national security review is pending. In 2024, the CNIPA reported that 47 patent assignment applications involving Hong Kong-listed companies were subject to extended review, with 3 ultimately blocked due to national security concerns. This directly affects the stability of the R&D team’s intellectual property ownership, a core component of the HKEX’s assessment.

Strategic Responses and Best Practices

Structuring Employment Contracts for HKEX Compliance

To pre-empt HKEX scrutiny, applicants should structure employment contracts for core R&D personnel to include: (i) a non-compete clause with a 12-month post-termination period, (ii) an automatic intellectual property assignment clause covering all inventions made during employment, and (iii) a provision requiring the employee to notify the company of any external engagements. The contracts should be governed by Hong Kong law or the law of the company’s place of incorporation to ensure enforceability. The sponsor should obtain legal opinions from counsel in the relevant jurisdictions confirming the enforceability of these clauses. In 2025, the HKEX accepted a legal opinion from a Hong Kong law firm as sufficient evidence for a Cayman-incorporated applicant, provided the opinion addressed the specific scenario of the employee’s relocation to the PRC.

Building a Redundant R&D Team Structure

Applicants should consider maintaining a minimum of three core technology personnel to avoid the “key person” dependency issue. This redundancy allows the company to demonstrate that the loss of any one individual would not materially impair R&D operations. The HKEX’s 2025 thematic review explicitly noted that applicants with four or more core technology personnel received fewer return comments on team stability. The additional personnel should be documented with the same level of contractual protection as the primary team members. For life sciences companies, the HKEX has accepted the inclusion of a senior clinical development director as a core technology personnel if that individual has contributed to the design of the applicant’s pivotal trials.

Proactive Disclosure in the Prospectus

The prospectus should include a dedicated section on “Stability of Core Technology and R&D Team” that provides: (i) a table listing each core technology personnel, their tenure, and their specific role in the company’s technology development, (ii) a summary of the contractual protections in place, and (iii) a risk factor addressing the potential impact of the departure of any core technology personnel. This disclosure should be cross-referenced to the sponsor’s due diligence findings. The HKEX’s 2025 listing decisions indicate that applicants who voluntarily provided this level of detail in their A1 submission reduced the number of subsequent return comments by an average of 35%.

Closing Actionable Takeaways

1. Verify that at least two core technology personnel have continuous tenure of three years or more, with employment contracts containing enforceable non-compete and IP assignment clauses, as required by HKEX Listing Decision HKEX-LD133-2024.
2. Obtain independent legal opinions from counsel in the PRC, Hong Kong, and the company’s place of incorporation confirming the enforceability of non-compete and IP assignment provisions, addressing cross-border regulatory risks.
3. Maintain a minimum of three core technology personnel to mitigate the “key person” dependency risk, and document a formal succession plan for any individual whose departure would materially impair R&D operations.
4. Register all PRC-originated patent assignments with the CNIPA and confirm that no national security review is pending, as required by the PRC’s 2024 Technology Security Management Regulations.
5. Include a dedicated “Stability of Core Technology and R&D Team” section in the prospectus with a detailed table of personnel, contractual protections, and risk factors, reducing the likelihood of return comments by approximately 35%.